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Abstract 
 
To evaluate trends in allografting from unrelated donors, we conducted a study on 196 consecutive 
myeloma patients transplanted between 2000 and 2009 in Italy. Twenty-eight percent, 37%, and 
35%, respectively, received myeloablative, reduced-intensity, and nonmyeloablative conditioning. 
In these 3 cohorts, 1-year and 5-year transplantation-related mortalities were 28.8% and 37.0%, 
20.3% and 31.3%, and 25.0% and 30.3%, respectively (P = .745). Median overall survival (OS) and 
event-free survival from transplantation for the 3 cohorts were 29 and 10 months, 11 and 6 months, 
and 32 and 13 months, respectively (P = .039 and P = .049). Overall cumulative incidences of acute 
and chronic graft-versus-host-disease (GVHD) were 46.1% and 51.1%. By Cox multivariate 
analyses, chronic GVHD was significantly associated with longer OS (hazard ratio [HR], .51; 
P = .009), whereas the use of peripheral blood stem cells was borderline significant (HR, .55; 
P = .051). Better response posttransplantation was associated with longer event-free survival (HR, 
2.13 to 4.25; P < .001). Acute GVHD was associated with poorer OS (HR, 2.53; P = .001). This 
analysis showed a strong association of acute and chronic GVHD and depth of response 
posttransplantation with clinical outcomes. Long-term disease control remains challenging 
regardless of the conditioning. In the light of these results, prospective trials may be designed to 
better define the role of allografting from unrelated donors in myeloma. 
 
Introduction 
 
Indications for allografting in the treatment of hematological malignancies have greatly changed 
over the past decade. Several changes in transplantation procedures and better supportive care have 
also contributed to significantly improve clinical outcomes [1]. Recent activity surveys by the 
European Group for Blood and Marrow Transplantation (EBMT) have shown that the number of 
allografts performed from unrelated donors is currently higher that those from HLA-identical 
siblings in Europe 2 and 3. As for plasma cell disorders, 569 allografts were performed in 2009 with 
a remarkable increase as compared with 2004 [2]. In particular, 546 allografts were performed for 
multiple myeloma in 2010 and over 50% were from unrelated donors [3]. Unfortunately, only a 
minority of patient were enrolled in prospective clinical trials. 
To observe trends and to report clinical outcomes in allografting from unrelated donors for the 
treatment of multiple myeloma in Italy, we conducted a retrospective study through the Italian Bone 
Marrow Donor Registry (IBMDR) over a 10-year period from 2000 to 2009 
(http://ClinicalTrials.gov; NCT01440556). 
 
Methods 
 
Patients 
 
From 2000 through 2009, 196 patients, median age 51 years (range, 32 to 67 years), underwent 
transplanted from an unrelated donor in Italy. Clinical data were retrieved from the central data 
management system Project Manager Internet Server (ProMISe) used by the EBMT and from the 
IBMDR where patients are followed longitudinally with at least yearly follow-up. Furthermore, 
patient forms for specific queries were sent to each participating center to complete data collection. 
The study was approved by the Italian Committee for Unrelated Donor Marrow Transplantation and 
by the institutional review board of the coordinating center, San Giovanni Battista Hospital, 
University of Torino, Torino, Italy, according to the Declaration of Helsinki 
(http://ClinicalTrials.gov; NCT01440556). 
 
Statistical Analysis 
 
Primary endpoints were overall survival (OS) from diagnosis and from the allograft and event-free 
survival (EFS) from the allograft. OS was defined as the date from diagnosis and from the allograft 
to death from any cause, whereas EFS was defined as the date from the allograft to disease 
progression/relapse or death from any cause, whichever occurred first. Alive patients without 
progression/relapse were censored as of March 31, 2012. Patient characteristics were compared 
with Fisher's exact test for categorical variables and with Mann-Whitney test for continuous 
variables. Survivals were calculated by the Kaplan-Meier method and analyzed by the Cox 
proportional hazards model, comparing the 2 arms by the Wald test and calculating 95% confidence 
intervals (CIs) 4 and 5. 
Univariate and multivariate analyses were performed for the following variables: Durie-Salmon 
stage, number of previous chemotherapy lines (>2 versus ≤2), exposure to “new drugs” 
(thalidomide, lenalidomide, bortezomib) before the allograft, disease status at transplantation, HLA-
matched alleles (≤8/10 versus 9/10 versus 10/10), recipient–donor gender combinations, stem cell 
source (bone marrow versus peripheral blood stem cells [PBSCs]), conditioning (nonmyeloablative 
versus reduced intensity versus myeloablative), acute graft-versus-host disease (GVHD), chronic 
GVHD, best response posttransplantation, and year of transplantation (2006 to 2009 versus 2003 to 
2005 versus 2000 to 2002). Conditionings were defined as myeloablative, reduced intensity or 
nonmyeloablative as previously described [6]. 
Response criteria were defined as complete remission (CR), partial remission (PR), and stable and 
progressive disease (SD-PD) according to the International Uniform Response Criteria for multiple 
myeloma [7]. Best response posttransplantation and acute and chronic GVHD were treated as time-
dependent variables. Moreover, to fully evaluate the confounding role of “disease status at 
transplantation” and “best response posttransplantation” in multivariate analyses, the previous Cox 
multivariate models were also estimated omitting these 2 variables. Cumulative incidences of 
grades II to IV acute GVHD, overall, limited and extensive chronic GVHD, and transplantation-
related mortality (TRM) were estimated by the Fine and Gray competing risk regression models as 
previously described [8]. TRM was defined as death without previous relapse. Death without acute 
GVHD was considered a competing risk for acute GVHD, whereas death without chronic GVHD 
for overall chronic GVHD, limited and extensive chronic GVHD, and relapse was considered a 
competing event for TRM. 
All P values were 2-sided at the conventional 5% significance level. Follow-up was updated as of 
March 31, 2012. Data were analyzed as of November 2012 by IBM SPSS 21.0. (Armonk, NY) and 
R 3.0.0 (R Foundation for Statistical Computing, Vienna, Austria) package cmprsk. 
 
Results 
 
Study Population 
 
Over the 10-year study period (January 2000 to October 2009), 649 unrelated volunteer donor 
searches for myeloma patients were started through the IBMDR. As of October 31, 2009, 196 
patients received transplantations after identifying a suitable unrelated donor at 34 centers; 3 
patients received 2 allografts for a total of 199 transplantations. Median time from the start of the 
donor search to transplantation was 7 months. Patient characteristics are reported in Table 1. 
Table 1.  
Characteristics of Patients Who Underwent an Allograft from an Unrelated Donor 
Characteristic Number 
Study period 2000-2009 
Patients 196 
Allografts 199 
Median age, yr (range) 51 (32-67) 
Male 120 (60%) 
Myeloma stage at diagnosis (Durie & Salmon)∗  
 Stage I-II 42 (21%) 
 Stage III 140 (70%) 
Myeloma isotype  
 IgG 115 (58%) 
 IgA 34 (17%) 
 IgM 1 (<1%) 
 Bence Jones 33 (16%) 
 Nonsecretory 3 (1%) 
Conditioning∗  
 Myeloablative 52 (28%) 
 Nonmyeloablative 64 (35%) 
 Reduced intensity 69 (37%) 
Therapy lines before transplant∗  
 ≤2 86 (43%) 
 >2 99 (50%) 
Recipient–donor HLA matched alleles  
 10/10 102 (52%) 
 9/10 62 (31%) 
 ≤8/10 34 (17%) 
Median time from diagnosis to transplant, mo 33 (range 5-171) 
∗ 
Data not reported in 14 transplants. 
 
 
Patients were also divided into 3 cohorts depending on the year of transplantation: 26 in 2000 to 
2002, 57 in 2003 to 2005, and 116 in 2006 to 2009. Patients were also divided by conditioning 
regimen: 52 were assigned the myeloablative conditioning regimen, 69 the reduced intensity, and 
64 the nonmyeloablative (conditioning regimen was unknown in 14 transplantations) (Figure 1). 
Patient median age at transplantation for the 3 cohorts was 45 years (range, 32 to 63 years), 53 years 
(range, 33 to 65 years), and 55 years (range, 38 to 67 years), respectively (P < .001). 
 
Figure 1.  
Number of allografts by year and trends in conditioning regimens over the study period. 
 
Therapy Lines 
 
Most patients were heavily pretreated and received a median of 3 (range, 1 to 7) lines of therapy 
before the allograft. One hundred fifty of 196 patients (76%) also received so-called new drugs: 71 
of 150 (47%) received thalidomide and/or lenalidomide, 28 of 150 (19%) received only bortezomib, 
and 51 of 150 (33%) received both thalidomide/lenalidomide and bortezomib. One hundred 
seventy-five of 196 patients (89%) had received at least 1 autograft; 12 of 196 (6%) had not 
undergone an autograft (data were missing in 9 patients [4%]). Median time from diagnosis and 
from the autograft to the unrelated donor allograft was 16 months (range, 2 to 150) and 33 months 
(range, 5 to 171), respectively. 
 
Conditioning Regimens, Stem Cell Source, and GVHD Prophylaxis 
 
Conditioning regimens 
 
Myeloablative regimens consisted primarily of cyclophosphamide–total body irradiation (TBI) and 
cyclophoshamide–busulfan. Some patients received high-dose busulfan associated with melphalan, 
fludarabine, or thiotepa–fludarabine. Other regimens included melphalan–cyclophosphamide–TBI, 
melphalan–TBI, and treosulphan–fludarabine. Nonmyeloablative regimens consisted of low-dose 
TBI (200 cGy) with fludarabine. Reduced-intensity regimens consisted of melphalan–fludarabine 
based or thiotepa–cyclophosphamide based conditionings. The use of myeloablative regimens 
remained steady during the study period, whereas reduced-intensity and nonmyeloablative regimens 
remarkably increased over the years (Figure 1, Table 2). 
 
 
 
 
 
 
 
 
Table 2.  
Transplant Characteristics of 3 Patient Cohorts Defined by Year of Transplant and 
Conditioning Regimen 
 
 
Year of 
Transplant 
Stem Cell 
Source 
No. of 
Transplants 
Therapy Lines 
Before Transplant 
No. of Patients 
Use of ATG 
No. of 
Transplants 
Conditioning 
Regimen∗ 
No. of Transplants 
BM vs. PBSC ≤2 vs. >2 Yes vs. No M vs. R vs. NM 
2000-2002 
21 (84%) vs. 5 
(19%) 
14 (54%) vs. 12 
(46%) 
18 (70%) vs. 8 
(30%) 
16 (70%) vs. 6 (26%) 
vs. 1 (4%) 
2003-2005 
12 (21%) vs. 45 
(79%) 
23 (40%) vs. 34 
(60%) 
29 (51%) vs. 28 
(49%) 
17 (32%) vs. 14 
(26%) vs. 22 (42%) 
2006-2009 
16 (14%) vs. 
100 (86%) 
61 (53%) vs. 55 
(47%) 
63 (55%) vs. 53 
(45%) 
19 (17%) vs. 49 
(45%) vs. 41 (38%) 
Conditioning 
Regimen∗ 
Stem Cell 
Source 
No. of 
Transplants 
Therapy Lines 
Before 
Transplant 
No. of Patients 
Use of ATG 
No. of 
Transplants 
Year of 
Transplant 
No. of Transplants 
BM vs. PBSC ≤2 vs. >2 Yes vs. No 
2000-2002 vs. 
2003-2005 vs. 
2006-2009 
Myeloablative 
24 (46%) vs. 
28 (54%) 
23 (44%) vs. 29 
(56%) 
45 (86%) vs. 7 
(14%) 
16 (31%) vs. 17 
(33%) vs. 19 (36%) 
Reduced intensity 
18 (26%) vs. 
51 (74%) 
33 (48%) vs. 36 
(52%) 
53 (77%) vs. 
16 (23%) 
6 (9%) vs. 14 (20%) 
vs. 49 (71%) 
Nonmyeloablative 
0 (0%) vs. 64 
(100%) 
30 (47%) vs. 34 
(53%) 
10 (16%) vs. 
54 (84%) 
1 (2%) vs. 22 (34%) 
vs. 41 (64%) 
BM indicates bone marrow; M, myeloablative; R, reduced intensity; NM, nonmyeloablative vs., 
versus. 
∗ 
Conditioning regimen was unknown in 14 transplants. 
 
Stem cell source 
 
PBSCs were the most frequently used stem cell source: They were used in 150 of 199 transplants 
(75%), whereas bone marrow was used in 49 of 199 transplants (25%). Bone marrow was primarily 
associated with myeloablative regimens in earlier years, whereas PBSCs were mostly used in 
reduced-intensity and in all nonmyeloablative regimens in recent years (Figure 1, Table 2). 
 
GVHD prophylaxis 
 
Myeloablative and reduced-intensity regimens were associated with cyclosporine–methothrexate 
based GVHD prophylaxis, whereas nonmyeloablative regimens were associated with cyclosporine–
mycophenolate mophetil prophylaxis. Moreover, antithymocyte globulin (ATG) was used in 110 of 
199 transplants (55%) as part of GVHD prophylaxis (Table 2). 
 
Transplant-Related Toxicity and Mortality 
 
Overall cumulative incidence of acute grades II to IV GVHD was 46.1%, whereas chronic GVHD 
was 51.1% (Figure 2A, B). The cumulative incidences of acute and chronic GVHD by type of 
conditioning were 41.2% and 42.9%, 50.0% and 40.1%, and 49.2% and 66.4% for myeloablative, 
reduced-intensity, and nonmyeloablative regimens, respectively. No statistically significant 
difference in acute GVHD cumulative incidence among the 3 cohorts was found (P = .803), 
whereas for chronic GVHD a borderline difference was observed (P = .052). 
 
 
Figure 2.  
(A) Cumulative incidence of acute grades II-IV GVHD. (B) Cumulative incidence of chronic 
GVHD. (C) Cumulative incidence of TRM. 
 
Overall cumulative incidence of TRM was 25.8% at 1 year and 33.2% at 5 years 
posttransplantation, and the cumulative incidence of its competing event (relapse) was 28.8% and 
50.0%, respectively (Figure 2C). One-year and 5-year TRM was 28.8% and 37.0%, 20.3% and 
31.3%, and 25.0% and 30.3% for myeloablative, reduced-intensity, and nonmyeloablative 
regimens, respectively (P = .745), whereas 1-year and 5-year cumulative incidences of relapse were 
21.2% and 46.0%, 42.1% and 54.3%, and 20.3% and 45.7%, respectively (P = .259). 
 
Disease Response 
 
At the time of the allograft, 29 of 196 patients (14.8%) were in CR and 87 of 196 (44.4%) in PR. 
Stratified by conditioning, patients in CR, PR, and SD-PD were 3 of 52 (6%), 23 of 52 (44%), and 
26 of 52 (50%) for myeloablative; 9 of 69 (13%), 28 of 69 (41%), and 32 of 69 (46%) for reduced-
intensity; and 15 of 64 (23%), 29 of 64 (45%), and 20 of 64 (31%) for nonmyeloablative regimens, 
respectively (P = .052). After a median follow-up from transplantation of 57 months (range, 3 to 
128), CR and PR in patients who survived at least 3 months after transplant were 40% and 39%, 
respectively, for an overall response rate of 79%. 
Clinical Outcomes 
At a median follow-up of 93 months (range, 25 to 189) from diagnosis, median OS from diagnosis 
of the entire study population was 67 months, whereas at a median follow-up of 57 months (range, 
3 to 128) posttransplantation, median OS and EFS from the allograft were 15 and 7 months, 
respectively (Figure 3A). Overall, 57 of 196 patients died of disease progression, whereas 71 of 196 
died of transplant-related causes. 
 
 
Figure 3.  
(A) OS and EFS from the allograft of the entire study population. (B) OS and EFS of 3 patient 
cohorts defined by conditioning regimen. (C) OS and EFS of 3 patient cohorts defined by year 
of transplantation. 
 
At a median follow-up of 120 months (range, 30 to 189), 76 months (range, 26 to 180), and 
93 months (range, 25 to 183) from diagnosis, median OS was 71, 66, and 67 months for 
myeloablative, reduced-intensity, and nonmyeloablative regimens, respectively (P = .362). At a 
median follow-up of 63 months (range, 3 to 128), 48 months (range, 10 to 103), and 58 months 
(range, 11 to 113) posttransplantation, median OS and EFS from the allograft were 29 and 
10 months, 11 and 6 months, and 32 and 13 months in patients who underwent myeloablative, 
reduced-intensity, and nonmyeloablative transplants, respectively (P = .039 and P = .049; 
Figure 3B). OS (P = .646) and EFS (P = .456) from the allograft in the 3 patient cohorts defined by 
year of transplantation are reported in Figure 3C. 
Factors Affecting OS and EFS 
By univariate analyses, lower number of therapy lines before the allograft, disease status at 
transplantation, a fully matched (10/10 alleles) HLA-identical donor, the use of PBSCs rather than 
bone marrow, and a better response posttransplantation were statistically significant variables for 
OS, whereas disease status at transplant, limited chronic GVHD, and a better response 
posttransplantation were statistically significant variables for EFS. 
However, by multivariate analyses, only the use of PBSCs (hazard ratio [HR], .55; P = .051) and 
the development of chronic GVHD (HR, .51; P = .009) were significant predictors for longer OS, 
whereas acute GVHD (HR, 2.53; P = .001) was a significant predictor for poorer OS. Most 
important predictors for EFS were a better response posttransplantation (PR versus CR: HR, 2.13; 
SD-PD versus CR: HR, 4.25; P < .001) and the conditioning regimen (reduced intensity versus 
myeloablative: HR, 1.96; P = .001). Complete univariate and multivariate analyses are reported in 
Tables 3 and 4. 
 
Table 3.  
Univariate and Multivariate Analyses (Cox Models) for OS 
Variable 
Univariate Analyses 
 
Multivariate Analyses 
 
HR 95% CI P HR 95% CI P 
Durie-Salmon stage (III vs. I-II) 1.27 .87-1.86 .218    
Previous therapy lines (>2 vs. ≤ 2) 1.54 1.09-2.17 .014 1.15 .71-1.88 .567 
Disease status at transplant   .009   .747 
 PR vs. CR 1.51 .84-2.71 .170 1.20 .49-2.93 .696 
 SD-PD vs. CR 2.25 1.26-4.01 .006 .98 .40-2.42 .965 
Recipient–donor HLA matched alleles   .010   .871 
 9/10 vs. 10/10 1.55 1.06-2.27 .025 1.14 .66-1.97 .642 
 ≤8/10 vs. 10/10 1.91 1.20-3.03 .006 1.16 .54-2.50 .697 
Recipient–donor gender combinations   .866    
 f.f. vs. m.f. 1.26 .70-2.29 .441    
 m.m. vs. m.f. 1.20 .74-1.93 .459    
 f.m. vs. m.f. 1.16 .69-1.97 .571    
New drugs before allograft (yes vs. no) .96 .65-1.41 .829    
Source (PBSC vs.BM) .60 .41-.87 .007 .55 .30-1.00 .051 
Conditioning   .042   .163 
 R vs M 1.26 .82-1.93 .293 1.46 .81-2.66 .211 
 NM vs. M .72 .45-1.15 .173 .86 .43-1.69 .655 
Acute GVHD∗ 1.49 .96-2.31 .078 2.53 1.50-4.28 .001 
Chronic GVHD∗ .67 .34-1.34 .258 .51 .31-.84 .009 
Variable 
Univariate Analyses 
 
Multivariate Analyses 
 
HR 95% CI P HR 95% CI P 
Chronic GVHD∗   .467    
Limited vs. no GVHD .66 .34-1.28 .220    
Extensive vs. no GVHD .80 .36-1.80 .597    
Best response posttransplantation∗   .011   .349 
 PR vs. CR .97 .53-1.80 .926 .82 .41-1.64 .580 
 SD-PD vs. CR 2.35 1.09-5.06 .030 1.35 .54-3.37 .520 
Year of transplant   .647    
 2003-2005 vs. 2000-2002 .82 .48-1.39 .453    
 2006-2009 vs. 2000-2002 .79 .48-1.30 .789    
f. indicates female; m., male; BM, bone marrow; R, reduced intensity; M, myeloablative; NM, 
nonmyeloablative, vs., versus. 
∗ 
Treated as a time-dependent variable. 
 
Table 4.  
Univariate and Multivariate Analyses (Cox Models) for EFS 
Variable 
Univariate Analyses 
 
Multivariate Analyses 
 
HR 95% CI P HR 95% CI P 
Durie-Salmon stage (III vs. I-II) 1.31 .93-1.85 .126    
Previous therapy lines (>2 vs. ≤ 2) 1.28 .94-1.75 .115 .97 .63-1.50 .895 
Disease status at transplant   .009   .605 
 PR vs. CR 1.83 1.08-3.11 .025 1.06 .49-2.30 .879 
 SD-PD vs. CR 2.28 1.34-3.89 .002 .85 .39-1.84 .674 
Recipient–donor HLA matched alleles   .095   .886 
 9/10 vs. 10/10 1.31 .92-1.86 .132 .92 .57-1.48 .731 
 ≤8/10 vs. 10/10 1.53 1.00-2.35 .050 1.08 .56-2.09 .820 
Recipient–donor gender combinations   .901    
 f.f. vs. m.f. 1.16 .67-1.99 .598    
 m.m. vs. m.f. 1.16 .76-1.78 .503    
 f.m. vs. m.f. 1.18 .74-1.89 .492    
New drugs before allograft (yes vs. no) .99 .70-1.41 .961    
Source (PBSC vs.BM) .75 .53-1.06 .098 1.02 .54-1.92 .951 
Conditioning   .052   .025 
 R vs. M 1.34 .90-2.00 .145 1.96 1.16-3.33 .001 
 NM vs. M .84 .56-1.27 .405 1.22 .71-2.08 .478 
ATG (yes vs. no) 1.08 .79-1.47 .645    
Acute GVHD∗ 1.12 .74-1.68 .593 1.15 .62-2.15 .658 
Variable 
Univariate Analyses 
 
Multivariate Analyses 
 
HR 95% CI P HR 95% CI P 
Chronic GVHD∗ .54 .31-.97 .040 .82 .45-1.50 .516 
Chronic GVHD∗   .047    
Limited vs. no GVHD .51 .29-.89 .017    
Extensive vs. no GVHD .55 .28-1.08 .082    
Best response posttransplantation∗   <.001   <.001 
 PR vs. CR 1.98 1.07-3.67 .029 2.13 1.34-3.41 .002 
 SD-PD vs. CR 4.85 2.29-1.29 <.001 4.25 2.41-7.50 <.001 
Year of transplant   .459    
 2003-2005 vs. 2000-2002 1.14 .69-1.89 .599    
 2006-2009 vs. 2000-2002 .92 .57-1.47 .722    
f. indicates female; m., male; BM, bone marrow; R, reduced intensity; M, myeloablative; NM, 
nonmyeloablative; vs., versus. 
∗ 
Treated as a time-dependent variable. 
 
By omitting “disease status at transplantation” and “best response posttransplantation” in the Cox 
multivariate models, major predictors for shorter OS remained acute GVHD (HR, 2.10; 95% CI, 
1.29 to 3.41; P = .003) and for longer OS chronic GVHD (HR, .42; 95% CI, .26 to .69; P = .001). 
Conditioning regimen (reduced intensity versus myeloablative: HR, 1.72; 95% CI, 1.04 to 2.84; 
P = .035) and chronic GVHD (HR, .48; 95% CI, .31 to .72; P < .001) were major predictors for 
EFS. 
 
Discussion 
 
The current role of allografting in multiple myeloma is controversial 9 and 10. The most recently 
published prospective studies were designed before new drugs with potent antimyeloma activity 
became readily available 11 and 12, enrolled newly diagnosed patients, used reduced-intensity or 
nonmyeloablative conditionings and donors were most frequently HLA-identical siblings 13, 14, 
15, 16, 17, 18, 19, 20, 21, 22 and 23. Conflicting results were reported. Only a few published 
reports focused on allografting from unrelated donors 24, 25, 26, 27 and 28. Our retrospective 
analysis through the IBMDR was intended to evaluate trends in allografting from unrelated donors 
over the past decade, with the ultimate goal of possibly offering recommendations to our centers on 
timing and type of allograft and on donor selection. 
In our experience, the number of allografts gradually increased over the study period. Overall, TRM 
at 1 year and 5 years was 25.8% and 33.2%, respectively. There was no significant difference in 
TRM (P = .745) between conditioning regimens. Incidence of acute GVHD was not significantly 
different among the 3 cohorts, whereas that of chronic GVHD was borderline significantly different 
(P = .052). Nonmyeloablative regimens showed a higher cumulative incidence of chronic GVHD, 
presumably related to the use of PBSCs. Patients conditioned with reduced-intensity or 
nonmyeloablative regimens were significantly older than those conditioned with a myeloablative 
regimen (P < .001). This is not irrelevant given that the median age of newly diagnosed myeloma 
patients is 67 to 68 years. Median OS and EFS of the entire study population were 15 and 7 months, 
respectively, and a subset have become long-term disease-free survivors ( Figure 3A). Even though 
this study cannot offer a formal comparison among conditionings, significant differences in both OS 
and EFS were observed among the 3 patient cohorts defined by conditioning ( Figure 3B). 
By multivariate analyses, acute and chronic GVHD were variables significantly associated with OS, 
whereas the use of a myeloablative conditioning and best response posttransplantation significantly 
correlated with EFS (Tables 3 and 4). The real impact of ATG on GVHD incidence could not 
formally be assessed because ATG was almost invariably associated with myeloablative and 
reduced-intensity conditionings. The impact of antileukemia effects associated with chronic GVHD 
was documented in many reports 29, 30 and 31. 
With regard to the association between chronic GVHD and graft-versus-myeloma effects, reports 
are somewhat conflicting 17, 19, 32, 33 and 34. Ringdén et al. evaluated the impact of acute and 
chronic GVHD on relapse and survival in a cohort of 177 patients who received an allograft from 
HLA-identical siblings after nonmyeloablative or reduced-intensity conditionings [34]. Acute 
GVHD was significantly correlated with increased risk of TRM, whereas limited chronic GVHD 
significantly lowered the risk of myeloma recurrence. However, in their retrospective experience, 
the reduced relapse risk did not translate into better OS [34]. In contrast, another study by Crawley 
et al. reported that chronic GVHD was associated with better progression-free survival and OS after 
reduced-intensity conditioning [33]. In prospective studies, Björkstrand et al. did not report any 
difference in OS and EFS between patients with and without chronic GVHD after nonmyeloablative 
conditioning [20]. Similar findings were reported by others 17 and 19. Differences from study to 
study may be due to the design of the Cox multivariate models: By omitting “disease status at 
transplantation” and “best response post-transplant” in our multivariate analyses, acute GVHD was 
a major predictor of poorer OS (HR, 2.10; P = .003) and chronic GVHD of significantly better OS 
(HR, .42; P = .001) and EFS (HR, .48; P < .001). 
Even though best response posttransplantation was the strongest predictor of better EFS but not of 
OS, this finding stresses the importance of depth of response 35 and 36. Consolidation and/or 
maintenance with new drugs may be a widely applicable option to explore. The efficacy of new 
drugs such as thalidomide and bortezomib in patients relapsed after an allograft has been reported in 
several studies 37 and 38. Furthermore, profound “immunomodulary effects” after allografting have 
already been observed. Higher response rates to salvage therapies, which translated into better OS, 
were reported in patients who had received a prior allograft rather than an autograft in a 
comparative study [19]. However, new drugs, such as lenalidomide, should be incorporated in 
clinical protocols as consolidation and/or maintenance with a degree of caution given that recently 
reported toxicity may be partly related to doses and treatment schedule [39]. Other strategies may 
include pre-emptive donor lymphocyte infusions with/without new drugs 40 and 41. 
Our study did not allow for a comprehensive analysis of the impact of cytogenetic abnormalities 
because most patients were diagnosed when standard cytogenetic or FISH analyses had not yet 
become part of the diagnostic work-up. Research showed that abnormalities such as del(17p) are 
associated with shorter response duration and poor prognosis even after treatment with “new drugs” 
[42]. A retrospective analysis by the Société Francaise de Greffe de Moelle et de Thérapie 
Cellulaire showed that patients who carry these high-risk abnormalities may most benefit from an 
allograft [43]. With the introduction of new drugs, allografting has gradually become a less 
attractive treatment option. However, prospective studies may evaluate its current role in selected 
high-risk and/or refractory patients earlier in the course of the disease to limit the risk of cumulative 
toxicity and the potential emergence of plasma cell clones resistant to graft-versus-myeloma effects. 
Before the introduction of reduced-intensity and/or nonmyeloablative conditioning, TRM was 
unacceptably high, up to 60% 44, 45 and 46. The wider use of reduced-intensity conditioning has 
recently shifted the burden of myeloma eradication and control from the pretransplantation 
intensive chemoradiotherapy of the conditioning to graft-versus-myeloma effects. A retrospective 
EBMT analysis showed that reduced-intensity conditioning was associated with less TRM but 
higher risk of relapse as compared with myeloablative conditioning [47]. It may be worth revisiting 
the role of more intense conditioning. Comorbidity scores, specifically designed for hematopoietic 
cell transplantations, may help to choose the intensity of the conditioning and to better select 
patients 48 and 49. Moreover, high-resolution HLA typing at an allele level is currently more 
readily available for both class I and II MHC antigens in donor registries, and a fully matched HLA 
donor should be highly preferable. Unlike other reports, however, we did not find any correlation 
between donor gender and clinical outcomes [50]. 
In summary, younger medically fit patients, with high-risk cytogenetics, may be offered more 
intense conditionings to combine profound cytoreduction and potential graft-versus-myeloma 
effects, whereas older unfit patients, because of comorbidities, may best benefit from debulking 
therapies followed by a reduced-intensity and/or nonmyeloablative allograft to avoid unacceptably 
high TRM. This treatment plan may be explored in future prospective control studies through the 
IBMDR. 
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